Refinement of IKZF1 status in pediatric Philadelphia-positive acute lymphoblastic leukemia

Leukemia

Volumn 29, Issue 10, 2015, Pages 2107-2110

  Lana, T ^a   De Lorenzo, P ^b   Bresolin, S ^a   Bronzini, I ^a   Den Boer, M L ^c,d   Cave H ^e   Fronkova E ^f   Stanulla, M ^g,h   Zaliova, M ^f,g,h   Harrison, C J ⁱ   De Groot, H ^d   Valsecchi, M G ^b   Biondi, A ^b   Basso, G ^a   Cazzaniga, G ^b   Te Kronnie, G ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; IKAROS TRANSCRIPTION FACTOR; IMATINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR IKZF1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; IKZF1 PROTEIN, HUMAN; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIMERIZATION; DISEASE FREE SURVIVAL; FRAMESHIFT MUTATION; GENE DELETION; GENE FREQUENCY; HUMAN; INCIDENCE; LETTER; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTICENTER STUDY; NEXT GENERATION SEQUENCING; PEDIATRICS; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; CLINICAL TRIAL; DNA SEQUENCE; GENETICS; MUTATION; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS;

BIOMARKERS, TUMOR; CHILD; COHORT STUDIES; GENE DELETION; HUMANS; IKAROS TRANSCRIPTION FACTOR; MUTATION; PHILADELPHIA CHROMOSOME; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SEQUENCE ANALYSIS, DNA;

EID: 84940916104     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.78     Document Type: Letter

References (15)

1. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936-945
2. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114
3. Van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 2014; 123: 1691-1698
4. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480
5. Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V, et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?. Haematologica 2013; 98: 1226-1231
6. Sun L, Liu A, Georgopoulos K. Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. EMBO J 1996; 15: 5358-5369
7. Schjerven H, McLaughlin J, Arenzana TL, Frietze S, Cheng D, Wadsworth SE, et al. Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat Immunol 2013; 14: 1073-1083
8. Cobb BS, Morales-Alcelay S, Kleiger G, Brown KE, Fisher AG, Smale ST. Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. Genes Dev 2000; 14: 2146-2160
9. Kastner P, Dupuis A, Gaub M-P, Herbrecht R, Lutz P, Chan S. Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res 2013; 3: 1-13
10. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22: 153-166
11. Aricò M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010; 28: 4755-4761
12. Kohlmann A, Klein H-U, Weissmann S, Bresolin S, Chaplin T, Cuppens H, et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia 2011; 25: 1840-1848
13. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249
14. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001; 11: 863-874
15. Raetz EA, Carroll WL. Refining prognosis in BCR-ABL1-positive ALL. Blood 2014; 123: 1626-1627